Michael Yee
Stock Analyst at Jefferies
(3.05)
# 1,384
Out of 5,005 analysts
78
Total ratings
43.4%
Success rate
13.37%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $2.18 | +37.61% | 5 | Mar 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $15.06 | +32.80% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $159.88 | +12.58% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $403.30 | +36.37% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $297.89 | +27.56% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $15.42 | +191.83% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $28.49 | +93.05% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $16.69 | +109.71% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $19.79 | +102.12% | 1 | Sep 13, 2024 | |
| AXON Axon Enterprise | Initiates: Buy | $385 | $715.51 | -46.19% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $3.71 | +169.54% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $6.05 | -50.41% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $25.75 | +16.50% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $18.84 | +6.16% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $37.47 | -46.62% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $10.07 | +644.79% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $3.60 | +733.33% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $34.21 | +90.00% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,875 → $1,125 | $11.73 | +9,490.79% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $3.30 | +809.09% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $9.92 | +202.42% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $23.29 | +415.24% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $20.59 | +264.25% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $35.65 | -15.85% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $17.40 | +342.53% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $112.69 | - | 3 | Jan 26, 2018 |
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $2.18
Upside: +37.61%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $15.06
Upside: +32.80%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $159.88
Upside: +12.58%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $403.30
Upside: +36.37%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $297.89
Upside: +27.56%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $15.42
Upside: +191.83%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $28.49
Upside: +93.05%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $16.69
Upside: +109.71%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $19.79
Upside: +102.12%
Axon Enterprise
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $715.51
Upside: -46.19%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $3.71
Upside: +169.54%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $6.05
Upside: -50.41%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $25.75
Upside: +16.50%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $18.84
Upside: +6.16%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $37.47
Upside: -46.62%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $10.07
Upside: +644.79%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $3.60
Upside: +733.33%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $34.21
Upside: +90.00%
Mar 2, 2021
Downgrades: Hold
Price Target: $1,875 → $1,125
Current: $11.73
Upside: +9,490.79%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $3.30
Upside: +809.09%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $9.92
Upside: +202.42%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $23.29
Upside: +415.24%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $20.59
Upside: +264.25%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $35.65
Upside: -15.85%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $17.40
Upside: +342.53%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $112.69
Upside: -